Laurus Labs Ltd (LAURUSLABS)
🎯 Key Takeaways
- Laurus Labs is in a high-growth phase driven by strategic expansion in CDMO and affordable medicines, supported by strong margin expansion and significant reinvestment in future capacity. Management is executing a clear plan to scale specialized manufacturing across peptides, gene therapy, and ADCs, underpinned by ESG commitments and capital discipline.
- Revenue grew 11.9% QoQ to ₹2,026 in Q1FY27.
- ⚠️ Execution risk in large-scale CAPEX projects — delays or cost overruns in new capacity additions could pressure returns.
📖 The Story
Laurus Labs is in a high-growth phase driven by strategic expansion in CDMO and affordable medicines, supported by strong margin expansion and significant reinvestment in future capacity. Management is executing a clear plan to scale specialized manufacturing across peptides, gene therapy, and ADCs, underpinned by ESG commitments and capital discipline.
📰 What's Happening
In Q1 FY27, Laurus Labs delivered 29% YoY revenue growth to ₹2,026 crores, with EBITDA up 66% and net profit surging 126%, reflecting improved operational leverage and margin expansion (gross margin at 62.7%, EBITDA margin at 31.8%). Management highlighted progress on ADC in-licensing, land acquisition, and CAPEX allocation of 85% to growth initiatives in peptides, gene therapy, and small molecules. A demerger of Laurus Synthesis is underway, with NCLT approval secured and next hearing scheduled for September 10, 2026. Additionally, 62,635 shares were allotted to employees via ESOP exercise on July 27, 2026, increasing paid-up capital. The board also approved unaudited Q1 FY27 results showing robust profitability and affirmed CAPEX at 19% of revenue to sustain growth investments.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1,653 | 1,778 | 1,812 | 2,026 |
| Operating Profit | 283 | 360 | 390 | 514 |
| OPM % | 17.1% | 20.2% | 21.5% | 25.4% |
| Net Profit | 194 | 253 | 282 | 362 |
| EPS | ₹3.61 | ₹4.67 | ₹5.17 | ₹6.81 |
The company is transitioning from early growth to scalable profitability, with revenue growing at a compounding pace (up 22% sequentially from Dec 2025 to Jun 2026) and margins expanding significantly — gross margin up 3.3 pts and EBITDA margin up 7 pts YoY. This improvement stems from scale in CDMO operations and better cost absorption, as highlighted in management commentary. CAPEX remains elevated at ₹394 crores in Q1 FY27 (19% of revenue), with 85% directed toward growth projects, indicating sustained investment in capacity ahead of demand. Profitability is accelerating, with net profit margin reaching 18% in Q1 FY27, up from 14.2% in the previous quarter, signaling successful execution of the business model.
🔮 Management Outlook & What's Next
Management expects sustained growth through strategic investments in peptides, gene therapy, and ADCs, with CAPEX planned to increase over FY27 and FY28 to support pipeline expansion. They have set SBTi targets for 42% Scope 1+2 GHG reduction by FY31 and 51.6% intensity reduction, reflecting a long-term commitment to sustainability. The company is focused on scaling CDMO and affordable medicines segments, with no dividend declared to preserve capital for reinvestment. The pending demerger of Laurus Synthesis is viewed as a value-unlocking move, with next steps expected at the September 10, 2026 NCLT hearing.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 108 | 108 | 108 | 108 |
| Reserves | 4,026 | 4,365 | 4,697 | 5,192 |
| Borrowings | 2,789 | 2,764 | 2,212 | 2,397 |
| Total Liabilities | 8,729 | 9,336 | 9,415 | 10,511 |
| Fixed Assets | 3,573 | 3,858 | 3,978 | 4,371 |
| Investments | 127 | 233 | 261 | 309 |
| Total Assets | 8,729 | 9,336 | 9,415 | 10,511 |
The balance sheet shows a healthy capital structure with equity of ₹108 crores and reserves growing to ₹5,192 crores as of March 2026, up from ₹4,365 crores a year ago. Borrowings have declined to ₹2,397 crores from ₹2,764 crores, indicating deleveraging momentum. Total assets have risen to ₹10,511 crores, reflecting successful capital deployment into growth initiatives. The company maintains a conservative debt-to-equity ratio of 0.45, supporting financial flexibility amid aggressive CAPEX plans.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +1,624 |
| Investing | -1,089 |
| Financing | -525 |
| Net Cash Flow | +10 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 27.6% | 27.5% | 27.5% | 27.5% |
| FII | 26.2% | 26.5% | 25.8% | 28.0% |
| DII | 11.7% | 12.4% | 14.0% | 13.7% |
| Public | 23.3% | 22.6% | 21.2% | 20.5% |
| # Shareholders | 2,83,678 | 2,80,756 | 2,92,281 | 2,91,653 |
Promoter holding remains stable at ~27.5%, but FII ownership has increased from 25.82% in Q4FY26 to 28% in Q1FY27, suggesting institutional confidence. DII holdings rose to 13.74% from 12.43% in Q3FY26, while public shareholding declined slightly to 20.49%. The number of shareholders has grown to 2,91,653, indicating broadening retail interest. No significant selling by promoters or institutions is evident, with minor fluctuations reflecting passive trading rather than strategic exits.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.61 L Cr | 38.1 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.46 L Cr | 84.1 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.92 L Cr | 80.3 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.18 L Cr | 26.4 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.15 L Cr | 34.0 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.05 L Cr | 95.5 | 20.8% | 20.6% | 0.45 |
| LUPIN | 99,448 | 17.6 | 27.9% | 24.7% | 0.26 |
| MANKIND | 98,599 | 48.2 | 13.9% | 12.7% | 0.38 |
| DRREDDY | 98,308 | 30.4 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 94,937 | 25.8 | 12.8% | 9.8% | 0.20 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Execution risk in large-scale CAPEX projects — delays or cost overruns in new capacity additions could pressure returns. 2. Regulatory and approval risks tied to the pending demerger and ADC in-licensing strategy, which are critical for future growth. 3. Margin sustainability — while current expansion is strong, maintaining 30%+ EBITDA margins will depend on competitive dynamics in the CDMO space. 4. ESG compliance costs — while targets are set, transitioning to low-carbon manufacturing may require additional investment beyond current CAPEX plans.
📋 Recent Filings
-
Announcement 12 August 2026Laurus Labs announced its participation in the Motilal Oswal Annual Global Investor Conference on August 19, 2026, in Mumbai, offering one-on-one and ...
-
Announcement 10 August 2026Laurus Labs Limited announced that NSE Sustainability Ratings and Analytics independently assigned an ESG Score of 63 out of 100 for FY 2026, based on...
-
Announcement 30 July 2026Laurus Labs reported Q1 FY27 revenue of INR2,026 crores, up 29% YoY, with EBITDA margin expanding to 31.8% and PAT at INR368 crores. CDMO revenue grew...
-
🔴 Corporate Action 27 July 2026Laurus Labs allotted 62,635 equity shares of Rs.2 each to employees exercising stock options across three schemes on July 27, 2026, increasing paid-up...
-
🔴 Corporate Action 25 July 2026Laurus Labs announced that the National Company Law Tribunal approved its scheme to demerge Laurus Synthesis Private Limited and amalgamate its remain...
-
🔴 Financial Results 24 July 2026Laurus Labs reported Q1 FY27 revenue of **₹2,026 crores**, up 29% YoY, driven by strong CDMO growth and Affordable Medicines momentum. Gross margins e...
-
🟡 Board Meeting 24 July 2026Laurus Labs announced the retirement of Dr. Rajesh Koshy Chandy as an Independent Director effective July 26, 2026, after completing his second term. ...
-
🟡 Board Meeting 24 July 2026Laurus Labs approved unaudited standalone and consolidated financial results for Q1 FY2026 ending June 30, 2026, showing revenue of **₹2,035.49 crores...
-
🔴 Financial Results 24 July 2026Laurus Labs reported Q1 FY27 revenue of ₹2,026 crores, up 29% YoY, driven by strong CDMO growth and expanded profitability. Gross margins rose to 62.7...
-
share transfer 14 July 2026Laurus Labs received share transfer agent certificates from KFin Technologies for the quarter ended June 30, 2026, confirming compliance with SEBI's R...
🧠 Analyst's Read
Laurus Labs is transitioning into a scalable CDMO player with improving profitability and clear capital allocation discipline. The key near-term catalyst is the NCLT decision on the demerger, which could re-rate the company by unlocking value in separated businesses. Investors should monitor progress on CAPEX execution and margin trends in the peptides and gene therapy segments.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when LAURUSLABS files new disclosures
Track LAURUSLABS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LAURUSLABS — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd